US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Veradermics, Inc.

126.63

+15.6814.13%

Pre-market: 124.92-1.7100-1.35%05:19 EDT

Volume:3.49M

Turnover:442.93M

Market Cap:5.29B

PE:-19.65

High:136.72

Open:111.60

Low:110.56

Close:110.95

52wk High:136.72

52wk Low:32.00

Shares:41.78M

Float Shares:32.29M

Volume Ratio:5.48

T/O Rate:10.81%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-6.4439

EPS(LYR):-111.9114

ROE:-72.06%

ROA:-43.45%

PB:6.50

PE(LYR):-1.13

Loading ...

Overview Company News Filings

Needham Initiates VeraDermics at Buy With $136 Price Target

MT Newswires Live

Veradermics Inc : Needham Initiates Coverage With Buy Rating; Price Target $136

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik

Veradermics to Present at Jefferies Global Healthcare Conference

Veradermics to present Phase 2/3 topline data for VDPHL01 oral minoxidil in male pattern hair loss at May 2026 congress

Advantage Capital invests $5.9 million in Veradermics via InvestCT Series B

Veradermics Is Maintained at Buy by Citigroup

Cerebras Swings IPO Focus to Tech and AI. But Healthcare and Industrials Still Lead. -- Barrons.com

Veradermics, Incorporated (MANE) Receives a Buy from Jefferies

Veradermics Hair Loss Data And Funding Reignite Interest In MANE Stock

Simply Wall St.

Veradermics Faces Financing Risk as Cashless Pre-Funded Warrants Offer Little to No Capital Infusion

Veradermics Q1 Net Loss Widens

MT Newswires Live

Veradermics reports Q1 net income ($27.2M) vs ($12.4M) last year

Veradermics releases corporate deck outlining VDPHL01 oral minoxidil program for pattern hair loss

Earnings Flash (MANE) Veradermics Posts Q1 Net Loss $27.2M, vs. FactSet Est of $22.9M Loss

MT Newswires Live

Veradermics Q1 FY26 net loss widens to $27.2 million; R&D expenses rise to $20.9 million

Veradermics Inc - Cash, Cash Equivalents and Marketable Securities Total $390.8 Mln as of March 31, 2026

THOMSON REUTERS

Press Release: Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics files initial beneficial ownership statement by Seven Fleet Capital Management LP

Veradermics Boosts Capital Through Public Offering and Warrants

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/MANE/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MANE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MANE\",,,,,undefined,":{"symbol":"MANE","market":"US","secType":"STK","nameCN":"Veradermics, Inc.","latestPrice":126.63,"timestamp":1791489600000,"preClose":110.95,"halted":0,"volume":3490511,"hourTrading":{"tag":"盘前","latestPrice":124.92,"preClose":126.63,"latestTime":"05:19 EDT","volume":26,"amount":3247.61008,"timestamp":1791537583900,"change":-1.71,"changeRate":-0.013504,"amplitude":0.000474},"delay":0,"changeRate":0.14132492113564663,"floatShares":32290700,"shares":41778687,"eps":-6.443948,"marketStatus":"Pre-Mkt","change":15.68,"latestTime":"10-09 05:23:39 EDT","open":111.6,"high":136.715,"low":110.56,"amount":442931046.13335997,"amplitude":0.235737,"askPrice":142.2,"askSize":100,"bidPrice":111.57,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-6.443948,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791552600000},"marketStatusCode":1,"adr":0,"listingDate":1770181200000,"exchange":"NYSE","adjPreClose":126.63,"preHourTrading":{"tag":"盘前","latestPrice":124.92,"preClose":126.63,"latestTime":"05:19 EDT","volume":26,"amount":3247.61008,"timestamp":1791537583900,"change":-1.71,"changeRate":-0.013504,"amplitude":0.000474},"postHourTrading":{"tag":"盘后","latestPrice":126,"preClose":126.63,"latestTime":"19:56 EDT","volume":6110,"amount":773199.2667,"timestamp":1791503816611,"change":-0.63,"changeRate":-0.004975,"amplitude":0.00598},"volumeRatio":5.47667904053933,"impliedVol":1.2597,"impliedVolPercentile":1},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MANE\",,,,,undefined,":{"symbol":"MANE","floatShares":32290700,"roa":"-43.45%","roe":"-72.06%","lyrEps":-111.911419,"volumeRatio":5.47667904053933,"shares":41778687,"dividePrice":0,"high":136.715,"amplitude":0.235737,"preClose":110.95,"low":110.56,"week52Low":32,"pbRate":"6.50","week52High":136.715,"institutionHeld":0,"latestPrice":126.63,"eps":-6.443948,"divideRate":0,"volume":3490511,"delay":0,"ttmEps":-6.443948,"open":111.6,"prevYearClose":17,"prevWeekClose":116.76,"prevMonthClose":121.23,"prevQuarterClose":121.23,"fiveDayClose":117.22,"twentyDayClose":98.14,"sixtyDayClose":123.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MANE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"MANE","fiscalQuarterEnding":"2026/06","expectedEps":-0.58,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.58}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MANE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MANE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1784174400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MANE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MANE","date":"2026-10-07","current":-19.650997,"percent":0.431953,"low":-67.545361,"twenty":-53.643529,"median":-47.365301,"eighty":-35.571997,"high":-9.296992,"avg":-45.829099,"sd":10.305782,"marketCap":4552363618},"quantilePoints":[{"date":"2026-02-06","current":-25.786263,"twenty":-25.079893,"median":-17.8457,"eighty":-10.368249,"marketCap":1387507243},{"date":"2026-02-13","current":-30.838039,"twenty":-29.065754,"median":-25.786263,"eighty":-19.198356,"marketCap":1659333205},{"date":"2026-02-20","current":-33.530469,"twenty":-32.062123,"median":-28.069277,"eighty":-25.043809,"marketCap":1804207481},{"date":"2026-02-27","current":-29.776333,"twenty":-31.085076,"median":-29.967163,"eighty":-25.732137,"marketCap":1602204947},{"date":"2026-03-06","current":-33.738647,"twenty":-32.654736,"median":-30.560469,"eighty":-26.152655,"marketCap":1815409101},{"date":"2026-03-13","current":-35.785726,"twenty":-33.721993,"median":-31.049686,"eighty":-27.249057,"marketCap":1925558357},{"date":"2026-03-20","current":-39.491287,"twenty":-35.53175,"median":-31.816474,"eighty":-28.546698,"marketCap":2124947181},{"date":"2026-03-27","current":-46.874652,"twenty":-39.507941,"median":-32.867771,"eighty":-29.468231,"marketCap":2522231279},{"date":"2026-04-02","current":-31.356106,"twenty":-39.513493,"median":-32.867771,"eighty":-29.852665,"marketCap":2194770608},{"date":"2026-04-10","current":-31.99758,"twenty":-38.92088,"median":-32.857362,"eighty":-30.17702,"marketCap":2239670594},{"date":"2026-04-17","current":-39.540857,"twenty":-39.536494,"median":-33.608872,"eighty":-30.279902,"marketCap":2767662294},{"date":"2026-04-24","current":-36.942854,"twenty":-39.536494,"median":-33.738647,"eighty":-30.421684,"marketCap":2585815082},{"date":"2026-05-01","current":-52.813611,"twenty":-40.831905,"median":-34.49692,"eighty":-30.615983,"marketCap":3696688710},{"date":"2026-05-08","current":-63.45616,"twenty":-42.963163,"median":-35.411007,"eighty":-30.844978,"marketCap":4441613943},{"date":"2026-05-15","current":-51.496667,"twenty":-46.59847,"median":-35.988193,"eighty":-30.890717,"marketCap":4368307751},{"date":"2026-05-22","current":-50.831536,"twenty":-50.412067,"median":-36.702792,"eighty":-31.015444,"marketCap":4311886693},{"date":"2026-05-29","current":-50.670085,"twenty":-50.670085,"median":-37.508333,"eighty":-31.226637,"marketCap":4298191318},{"date":"2026-06-05","current":-49.857433,"twenty":-50.482929,"median":-39.295461,"eighty":-31.282151,"marketCap":4229256485},{"date":"2026-06-12","current":-46.493546,"twenty":-50.049515,"median":-39.519044,"eighty":-31.356106,"marketCap":3943908052},{"date":"2026-06-18","current":-45.24748,"twenty":-50.006173,"median":-40.004977,"eighty":-31.7244,"marketCap":3838207974},{"date":"2026-06-26","current":-58.79168,"twenty":-50.634624,"median":-40.906894,"eighty":-31.961359,"marketCap":4987121867},{"date":"2026-07-02","current":-63.278505,"twenty":-51.067836,"median":-42.661209,"eighty":-32.20951,"marketCap":5367725705},{"date":"2026-07-10","current":-61.520221,"twenty":-53.048338,"median":-44.057315,"eighty":-32.416525,"marketCap":5218575793},{"date":"2026-07-17","current":-52.123009,"twenty":-54.2625,"median":-44.976596,"eighty":-32.698555,"marketCap":4421438445},{"date":"2026-07-24","current":-57.062948,"twenty":-54.490042,"median":-45.472923,"eighty":-32.869852,"marketCap":4840478675},{"date":"2026-07-31","current":-51.531989,"twenty":-54.856474,"median":-45.794173,"eighty":-33.139095,"marketCap":4371304020},{"date":"2026-08-07","current":-53.511905,"twenty":-54.832834,"median":-46.684099,"eighty":-33.593192,"marketCap":4539254342},{"date":"2026-08-14","current":-50.036631,"twenty":-54.832834,"median":-47.316049,"eighty":-33.69117,"marketCap":4637595096},{"date":"2026-08-21","current":-47.476198,"twenty":-54.602336,"median":-47.561116,"eighty":-33.713665,"marketCap":4400283923},{"date":"2026-08-28","current":-45.893958,"twenty":-54.263485,"median":-47.316049,"eighty":-33.861631,"marketCap":4253635646},{"date":"2026-09-04","current":-44.06379,"twenty":-54.197488,"median":-46.684099,"eighty":-34.12449,"marketCap":4084008294},{"date":"2026-09-11","current":-44.239594,"twenty":-54.067463,"median":-46.421397,"eighty":-34.344005,"marketCap":4100302547},{"date":"2026-09-18","current":-48.99082,"twenty":-53.916605,"median":-46.349247,"eighty":-34.830885,"marketCap":4540665180},{"date":"2026-09-25","current":-52.164315,"twenty":-53.806823,"median":-46.818058,"eighty":-35.200053,"marketCap":4834797337},{"date":"2026-10-02","current":-52.840485,"twenty":-53.806823,"median":-47.237246,"eighty":-35.451255,"marketCap":4897467541},{"date":"2026-10-07","current":-49.117039,"twenty":-53.643529,"median":-47.365301,"eighty":-35.571997,"marketCap":4552363618}],"updateTime":1791518812832},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MANE\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640911998","title":"Needham Initiates VeraDermics at Buy With $136 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2640911998","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640911998?lang=en_us&edition=fundamental","pubTime":"2026-06-02 17:51","pubTimestamp":1780393864,"startTime":"0","endTime":"0","summary":"Needham Initiates VeraDermics at Buy With $136 Price Target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640919148","title":"Veradermics Inc : Needham Initiates Coverage With Buy Rating; Price Target $136","url":"https://stock-news.laohu8.com/highlight/detail?id=2640919148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640919148?lang=en_us&edition=fundamental","pubTime":"2026-06-02 17:34","pubTimestamp":1780392861,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nFWN42A0E7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640913560","title":"U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik","url":"https://stock-news.laohu8.com/highlight/detail?id=2640913560","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640913560?lang=en_us&edition=fundamental","pubTime":"2026-06-02 15:49","pubTimestamp":1780386551,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik June 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Edgewise","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nL4N42A0K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAG","ORCU","NAVN","SAIL","ARXS","GOOGL","GOOY","CZR","UNX","OCTV","ALGT","BXMT","BWA","GOOX","EWTX","GOOW","HPE","ODTX","TMHC","GGLS","GH","MLM","RVMD","VMC","MOBI","U","GGLL","CPB","RBRK","FULC","SAIC","XFOR","GOU","CIEN","MAC","ORCX","ORCS","MANE","GOOP","ACRE","SOC","IBM","ORCL","BRKR","TTWO","LTH","BTSG","EW","PRAX","CHWY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639160196","title":"Veradermics to Present at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2639160196","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639160196?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:30","pubTimestamp":1780000254,"startTime":"0","endTime":"0","summary":"Veradermics will present at the Jefferies Global Healthcare Conference on June 3 in New York.Management will also present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8 in Miami.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL3RwTHv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0942090050.USD","LU2237443382.USD","LU2265009873.SGD","BK4504","IE0034235188.USD","BK4552","LU2237443622.USD","GSX","LU0345770993.USD","LU1868836591.USD","LU1791807156.HKD","LU0251142724.SGD","BK4007","LU2471134796.USD","IE0004091025.USD","IE00B19Z3581.USD","LU1868837300.USD","LU0106831901.USD","LU0048573561.USD","LU0345770308.USD","LU2750360641.GBP","LU1668664300.SGD","IE00B19Z3B42.SGD","LU1894683348.USD","BK4127","LU2237438978.USD","LU0096364046.USD","LU2237443895.HKD","LU0061475181.USD","LU1868836914.USD","BK4585","LU2237443978.SGD","LU2471134523.USD","LU2237443549.SGD","IE0004086264.USD","BK4516","BK4533","IE00BSNM7G36.USD","LU2750360997.AUD","LU0251131958.USD","LU1868836757.USD","LU1894683264.USD","BK4550","BK4588","IE00BFXG1179.USD","LU1804176565.USD","LU1868837136.USD","LU2237443465.HKD","LU2471134879.HKD","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638650267","title":"Veradermics to present Phase 2/3 topline data for VDPHL01 oral minoxidil in male pattern hair loss at May 2026 congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2638650267","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638650267?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:30","pubTimestamp":1779881421,"startTime":"0","endTime":"0","summary":"Veradermics set a May 30, 2026 poster at the World Congress for Hair Research to disclose topline Phase 2/3 Study 302 results for VDPHL01.Results were previously shared in April 2026, with the upcoming presentation positioned as a fuller public readout.Part A showed positive outcomes for VDPHL01, an extended-release oral minoxidil tablet, in more than 500 men with mild-to-moderate pattern hair loss.The readout supports plans to advance VDPHL01 as a potential FDA-approved oral pill for pattern hair loss, a category without a new pill in decades.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire  on May 27, 2026, and is solely responsible for ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL6GGBfk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636529758","title":"Advantage Capital invests $5.9 million in Veradermics via InvestCT Series B","url":"https://stock-news.laohu8.com/highlight/detail?id=2636529758","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636529758?lang=en_us&edition=fundamental","pubTime":"2026-05-19 22:17","pubTimestamp":1779200278,"startTime":"0","endTime":"0","summary":"Advantage Capital invested USD 5.9 million in Veradermics in February 2025 as part of the company’s Series B round through the InvestCT program.Veradermics later completed a USD 256 million IPO on the New York Stock Exchange.The company is developing an oral, non-hormonal treatment for pattern hair loss, with Phase 3 data expected this year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Advantage Capital Management Corp published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL8Bxtvh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636003650","title":"Veradermics Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2636003650","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636003650?lang=en_us&edition=fundamental","pubTime":"2026-05-19 02:07","pubTimestamp":1779127620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MANE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 18, 2026 14:07 ET (18:07 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635236744","title":"Cerebras Swings IPO Focus to Tech and AI. But Healthcare and Industrials Still Lead. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2635236744","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635236744?lang=en_us&edition=fundamental","pubTime":"2026-05-15 01:10","pubTimestamp":1778778600,"startTime":"0","endTime":"0","summary":"Investors are salivating over the initial public offering of Cerebras Systems. The artificial-intelligence chip company's IPO on Thursday is the biggest of 2026, raising $6.4 billion at a market valuation of about $55 billion. The stock opened at $350, nearly double its IPO price, once it began trading on the Nasdaq, under ticker symbol CBRS. It quickly surged to $385 before being halted for volatility.But even though Cerebras is cashing in on the AI craze, it's an anomaly this year. There actually haven't been many big tech IPOs -- at least not yet.Only five techs have gone public this year before Cerebras, according to data from IPO research and investing firm Renaissance Capital. And they have mostly underwhelmed. That may be largely because none of them were blockbuster deals. The largest was crypto firm  BitGo Holdings, which raised $213 million from its stock sale in late January. Shares have tumbled nearly 35% from their IPO price.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","ARTY","DXYZ","BK4127","FPS","BK4182","BK4528","BTGO","SPCX","LU0128526141.USD","XOVR","DBB","BK4023","AGIX","LABU","MANE","BK4581","IPOS","XLV","AI","AIYY","UFO","BK4587","BK4137","BK4585","CHAT","BK4588","BK4551","BK4007","HCSG","AIPO","XBI","LU0029874061.USD","CBRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635197744","title":"Veradermics, Incorporated (MANE) Receives a Buy from Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2635197744","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635197744?lang=en_us&edition=fundamental","pubTime":"2026-05-15 00:47","pubTimestamp":1778777259,"startTime":"0","endTime":"0","summary":"Jefferies analyst Roger Song maintained a Buy rating on Veradermics, Incorporated today and set a price target of $138.00. According to TipRanks, S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/veradermics-incorporated-mane-receives-a-buy-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/veradermics-incorporated-mane-receives-a-buy-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635799146","title":"Veradermics Hair Loss Data And Funding Reignite Interest In MANE Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2635799146","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635799146?lang=en_us&edition=fundamental","pubTime":"2026-05-14 14:47","pubTimestamp":1778741222,"startTime":"0","endTime":"0","summary":"Veradermics (NYSE:MANE) reported positive Phase 2/3 topline results for its oral pattern hair loss candidate VDPHL01, positioning it as a potential first new FDA-approved oral option in this category in almost 30 years.\nThe company also highlighted completion of enrollment in other key clinical studies and recent substantial funding to support ongoing programs.\nThe stock last closed at $107.14, with a 30 day return of 50.1% and a year to date return of 183.8%.\n\nFor investors watching...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/veradermics-hair-loss-data-and-funding-reignite-interest-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/veradermics-hair-loss-data-and-funding-reignite-interest-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635476088","title":"Veradermics Faces Financing Risk as Cashless Pre-Funded Warrants Offer Little to No Capital Infusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2635476088","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635476088?lang=en_us&edition=fundamental","pubTime":"2026-05-14 14:01","pubTimestamp":1778738501,"startTime":"0","endTime":"0","summary":"Veradermics, Incorporated (MANE) has disclosed a new risk, in the Debt & Financing category. Veradermics, Incorporated faces a financing risk becau...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/veradermics-faces-financing-risk-as-cashless-pre-funded-warrants-offer-little-to-no-capital-infusion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/veradermics-faces-financing-risk-as-cashless-pre-funded-warrants-offer-little-to-no-capital-infusion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216008","title":"Veradermics Q1 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216008","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216008?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:05","pubTimestamp":1778587537,"startTime":"0","endTime":"0","summary":"Veradermics  reported Tuesday its Q1 loss widened to $27.2 million, compared with a net loss of $12.4 million a year earlier.A single analyst polled by FactSet expected a loss of $18 million.The company did not report revenue during the quarter.Cash, cash equivalents and marketable securities totaled $390.8 million as of March 31. The company said those funds are expected to fund operations into 2030.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216781","title":"Veradermics reports Q1 net income ($27.2M) vs ($12.4M) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216781","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216781?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:57","pubTimestamp":1778587042,"startTime":"0","endTime":"0","summary":"Cash, cash equivalents, and marketable securities totaled $390.8 million as of March 31, 2026, reflecting net proceeds from the company’s upsized i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veradermics-reports-q1-net-income-27-2m-vs-12-4m-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veradermics-reports-q1-net-income-27-2m-vs-12-4m-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634215469","title":"Veradermics releases corporate deck outlining VDPHL01 oral minoxidil program for pattern hair loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2634215469","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634215469?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:37","pubTimestamp":1778585873,"startTime":"0","endTime":"0","summary":"Veradermics outlined late-stage plans for VDPHL01, an extended-release oral minoxidil tablet being developed for pattern hair loss, positioned to increase exposure for hair growth while keeping peak concentrations below cardiac activity thresholds.Topline data from Part A of Study 302 in males showed statistically significant gains in non-vellus target area hair count at month 6, with increases of 30.3 hairs for 8.5 mg once daily and 33.0 hairs for 8.5 mg twice daily versus 7.3 hairs for placebo.Confirmatory Phase 3 Study 304 in 552 males is fully enrolled, with a 6-month topline readout expected in H2 2026.Female program Study 306, a Phase 2/3 trial, is enrolling as company targets first FDA-approved oral option for women with pattern hair loss.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL9JXcQk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634215178","title":"Earnings Flash (MANE) Veradermics Posts Q1 Net Loss $27.2M, vs. FactSet Est of $22.9M Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2634215178","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634215178?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:35","pubTimestamp":1778585721,"startTime":"0","endTime":"0","summary":"Earnings Flash (MANE) Veradermics Posts Q1 Net Loss $27.2M, vs. FactSet Est of $22.9M Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634610215","title":"Veradermics Q1 FY26 net loss widens to $27.2 million; R&D expenses rise to $20.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634610215","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634610215?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:30","pubTimestamp":1778585440,"startTime":"0","endTime":"0","summary":"Veradermics posted a net loss of $27.2 million, widening from $12.4 million a year earlier.R&D expenses climbed to $20.9 million from $11.4 million.G&A costs rose to $8.9 million from $1.5 million.Cash, cash equivalents, and marketable securities increased to $390.8 million as of March 31, 2026; Veradermics later raised about $472 million in gross proceeds in a follow-on offering.Management cited positive Phase 2/3 topline results from Study 302 for VDPHL01; 12-month data from Study 302 and topline results from Phase 3 Study 304 are expected in second-half 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire  on May 12, 2026, and is solel","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL35qC3D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216314","title":"Veradermics Inc - Cash, Cash Equivalents and Marketable Securities Total $390.8 Mln as of March 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216314","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216314?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:30","pubTimestamp":1778585401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUABGSTNK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634917215","title":"Press Release: Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2634917215","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634917215?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:30","pubTimestamp":1778585400,"startTime":"0","endTime":"0","summary":"Positive topline results from Phase 2/3 Study '302' position VDPHL01 to potentially become the first FDA-approved oral treatment for pattern hair loss in nearly 30 years. Upsized IPO and follow-on financing generated approximately $766.8 million in aggregate gross proceeds; pro forma cash expected to fund operations into 2030 through multiple Phase 3 readouts and potential launch. Veradermics, Incorporated , a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate and clinical progress.\"The announcement of positive Phase 2/3 topline results from Study '302' in April 2026 was an inflection point for Veradermics and supports our belief that VDPHL01 can become a foundational treatment for pattern hair loss,\" said Reid Waldman, M.D., Chief Executive Officer of Veradermics. \"We are working with urgenc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","MANE","PRGS","LU2065732104.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633597536","title":"Veradermics files initial beneficial ownership statement by Seven Fleet Capital Management LP","url":"https://stock-news.laohu8.com/highlight/detail?id=2633597536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633597536?lang=en_us&edition=fundamental","pubTime":"2026-05-06 07:42","pubTimestamp":1778024579,"startTime":"0","endTime":"0","summary":"Veradermics filed Form 3 showing Seven Fleet Capital Management reported beneficial ownership of 80,000 shares of common stock held indirectly through managed funds.Filing dated May 5, 2026 cited May 1, 2026 as date of event triggering the ownership report.Seven Fleet checked box for 10% owner status.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL14LFWw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623599","title":"Veradermics Boosts Capital Through Public Offering and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623599","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632623599?lang=en_us&edition=fundamental","pubTime":"2026-05-02 05:52","pubTimestamp":1777672358,"startTime":"0","endTime":"0","summary":"Veradermics, Incorporated ( ($MANE) ) has shared an announcement. On May 1, 2026, Veradermics, Incorporated closed an underwritten public offering ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/veradermics-boosts-capital-through-public-offering-and-warrants?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/veradermics-boosts-capital-through-public-offering-and-warrants?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":114,"code":"91000000","status":"200"}]}}